Bavarian Nordic - Strengthens Commercial Focus; Pipeline Update
2007 OCT 1 -- Bavarian Nordic, the Danish-based biopharmaceutical company, announced it will establish a new separate sales and marketing function to strengthen the company's commercial activities and increase marketing efforts on its third-generation smallpox vaccine, IMVAMUNE(R) as well as future HIV and cancer vaccines. The new commercial affairs function will be headed up by an Executive Vice President who will join the Corporate Management group and refer to Anders Hedegaard, CEO. An appointment is expected before year-end. Bavarian Nordic sees great potential in the market for IMVAMUNE smallpox vaccine, as evidenced by the recent contract award(i) by the Department of Health and Human Services (HHS) to purchase 20 million doses of the company's vaccine. Bavarian Nordic is currently in negotiations with a number of other countries on the manufacture and delivery of IMVAMUNE, the timing and value of potential contracts is not yet known. Status on IMVAMUNE smallpox vaccine contract Keywords: Bioengineering, Bavarian Nordic GmbH, Biopharmaceuticals, Biotechnology, Biotechnology Business, Biotechnology Company, Vaccines, Bavarian Nordic A/S. This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.
|
